909. The Burden of Pneumococcal Community-Acquired Pneumonia and Invasive Pneumococcal Disease in Hospitalized Adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) Network Study
Session: Oral Abstract Session: Pneumonia from Soup to Nuts
Friday, October 28, 2016: 9:30 AM
Room: 288-290
Background:  Pneumococcal community acquired pneumonia (CAP) and invasive pneumococcal disease (IPD) cause significant morbidity and mortality worldwide. Although childhood immunization programs have reduced the burden of pneumococcal disease, there is insufficient data in Canada to advise immunization policy in adults. This study aimed to describe clinical outcomes of pneumococcal CAP and IPD in hospitalized Canadian adults, and determine the proportion of patients with vaccine-preventable disease.

Methods: To establish the burden of pneumococcal disease, active surveillance for CAP and IPD in hospitalized adults was performed in five Canadian provinces from December 2010 to 2013. The serotype distribution was characterized using the Quellung reaction, PCR-based serotyping, and urine antigen detection (UAD).

Results: Of 4769 cases of all-cause CAP, a laboratory test for pneumococci was performed in 3703. Of these, 516 (13.9%) were pneumococcal CAP (CAPSpn) and 238 (6.4%) were bacteremic CAPSpn. In addition to CAP, 80 cases of IPD (non-CAP) were identified. The burden of CAPSpn, bacteremic CAPSpn, and IPD was evident in terms of intensive care unit admission, mechanical ventilation, and 30-day mortality. Overall, the proportion of all-cause CAP with laboratory testing identifying a 13-valent pneumococcal conjugate vaccine (PCV13) or 23-valent pneumococcal polysaccharide vaccine (PPV23) serotype was 6.2% and 7.1%, respectively. However, these values are underestimated; 41.9% of the CAPSpn case isolates were not viable upon re-culturing, non-typeable, or unavailable for serotyping. Of the available serotypes, PCV13- and PPV23-serotypes represented 76.0% and 87.7% in CAPSpn, respectively. If these proportions are extrapolated to the overall contribution of CAPSpn to all-cause CAP of 13.9%, PCV13- and PPV23-serotypes would represent 10.6% and 12.2% of all-cause CAP, respectively. The results of a PCV13-specific UAD were consistent with this estimation at 197/1907 (10.3%).

Conclusion: This study demonstrated that pneumococcal CAP and IPD are significant causes of morbidity and mortality in hospitalized Canadian adults, with a large proportion of available S. pneumoniae serotypes being vaccine-preventable.

Jason Leblanc, PhD1, May Elsherif, MD1, Donna Mackinnon-Cameron, MMath1, Lingyun Ye, PhD1, Ardith Ambrose, RN1, Irene Martin, BSc2, Haley Gillis, BSc1, Amanda Lang, PhD1, Melissa K Andrew, MD, PhD1, Guy Boivin, MD, MSc3, William Bowie, MD, FRCPC, FIDSA4, Karen Green, MSc5, Todd Hatchette, MD1, Jennie Johnstone, MD6, Mark Loeb, MD, MSc6, Anne E. Mccarthy, MD7, Allison Mcgeer, MD, MSc5, Sanela Moraca, MHSc1, Makeda Semret, MD8, Grant Stiver, MD4, Sylvie Trottier, MD3, Louis Valiquette, MD, MSc9, Duncan Webster, MD10, Shelly a Mcneil, MD, FRCPC, FIDSA1 and on behalf of the CIRN SOS Network Investigators, (1)Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, NS, Canada, (2)National Microbiology Laboratory, Winnipeg, MB, Canada, (3)Centre Hospitalier Universitaire de Quebec, Quebec, QC, Canada, (4)University of British Columbia, Vancouver, BC, Canada, (5)Mount Sinai Hospital, Toronto, ON, Canada, (6)McMaster University, Hamilton, ON, Canada, (7)The Ottawa Hospital, Ottawa, ON, Canada, (8)McGill University, Montreal, QC, Canada, (9)Universite de Sherbrooke, Sherbrooke, QC, Canada, (10)Horizon Health, St. John, NB, Canada


J. Leblanc, None

M. Elsherif, None

D. Mackinnon-Cameron, None

L. Ye, None

A. Ambrose, None

I. Martin, None

H. Gillis, None

A. Lang, None

M. K. Andrew, GSK: Investigator , Research support

G. Boivin, Biocryst: Investigator , Research grant
Merck: Investigator , Research grant

W. Bowie, GSK: Investigator , Research grant

K. Green, None

T. Hatchette, GSK: Investigator , Research grant

J. Johnstone, None

M. Loeb, GSK: Investigator , Research support

A. E. Mccarthy, GSK: Investigator , Research support

A. Mcgeer, None

S. Moraca, None

M. Semret, None

G. Stiver, None

S. Trottier, None

L. Valiquette, None

D. Webster, None

S. A. Mcneil, GSK: Grant Investigator , Research grant and Research support
Pfizer: Grant Investigator , Consulting fee , Research grant , Research support and Speaker honorarium
Merck: Consultant and Investigator , Consulting fee , Research support and Speaker honorarium

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.